The US Food and Drug Administration (FDA) has strengthened a drug safety warning for a schizophrenia medication.

The US Food and Drug Administration (FDA) has approved a first-of-its-kind patch for schizophrenia.

Abilify MyCite is the first digital medication system approved by the US Food and Drug Administration (FDA).

The US Food and Drug Administration (FDA) has approved the first drug to treat tardive dyskinesia.

The US Food and Drug Administration (FDA) has approved a new treatment for teens with schizophrenia.

The US Food and Drug Administration (FDA) is warning about the possibility for a rare but serious skin reaction from a particular antipsychotic.

The US Food and Drug Administration (FDA) is warning about possible impulse-control problems, such as compulsive or uncontrollable urges, tied to a particular antipsychotic.

Patients with severe mental illness face an increased risk for diabetes. And new evidence suggests there may be room for improvement when it comes to screening these patients for the condition.

After a new FDA approval, patients who face schizophrenia every day may not have to take their medication every day to stay healthy.

A newly approved medication could help some patients with serious mental health disorders.